PFS Partners’s Novo Nordisk NVO Stock Holding History

PFS Partners’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.59K	Hold	200	–	–	﹤0.01%	386
2026 Q1	$7.35K	Buy	+200	New	+$9.48K	﹤0.01%	396
2025 Q4	–	Sell	-4	Closed	-$222	–	598
2025 Q3	$222	Hold	4	–	–	﹤0.01%	550
2025 Q2	$277	Hold	4	–	–	﹤0.01%	492
2025 Q1	$278	Hold	4	–	–	﹤0.01%	427
2024 Q4	$345	Hold	4	–	–	﹤0.01%	429
2024 Q3	$477	Hold	4	–	–	﹤0.01%	426
2024 Q2	$571	Hold	4	–	–	﹤0.01%	413
2024 Q1	$514	Hold	4	–	–	﹤0.01%	437
2023 Q4	$414	Sell	4 -6	-60%	-$593	﹤0.01%	436
2023 Q3	$915	Hold	10	–	–	﹤0.01%	430
2023 Q2	$812	Hold	10	–	–	﹤0.01%	449
2023 Q1	$796	Buy	+10	New	+$709	﹤0.01%	362

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

PFS Partners's NVO Position: Q2 2026 in Review

PFS Partners held its Novo Nordisk (NVO) position steady in Q2 2026 at 200 shares worth $9.59K. The position accounts for ﹤0.01% of the portfolio, ranked #386.

PFS Partners first reported a position in NVO in Q1 2023 and has held it in 13 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

PFS Partners held 200 shares of Novo Nordisk worth $9.59K as of Q2 2026.
PFS Partners left its Novo Nordisk share count unchanged in Q2 2026.
Novo Nordisk made up ﹤0.01% of PFS Partners's portfolio in Q2 2026, its #386 holding.
PFS Partners first reported a position in Novo Nordisk in Q1 2023 and has held it in 13 quarters since.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on PFS Partners's 13F filing for Q2 2026, filed 20 Jul 2026.